Global Information
회사소개 | 문의 | 비교리스트

세계의 인간 인슐린 시장 : 적응증별, 브랜드별, 투여 경로별, 종류별, 작용 발현 시간별, 제품별, 지역별 예측과 기회(2025년)

Global Human Insulin Market By Indication, By Brand, By Route of Administration, By Type, By Onset Time, By Products, By Region, Forecast & Opportunities, 2025

리서치사 TechSci Research
발행일 2020년 05월 상품 코드 934750
페이지 정보 영문 121 Pages
가격
US $ 4,450 ₩ 5,070,000 Unprintable PDF and Excel (Single User License)
US $ 5,450 ₩ 6,209,000 PDF and Excel (Multi-User License)
US $ 9,450 ₩ 10,767,000 PDF and Excel (Custom Research License)

TechSci Research 보고서는 10% Customization 서비스가 포함되어 있습니다. 보고서에 포함돼 있지 않은 리서치 데이터와 시장 동향을 추가적으로 요청할 수 있습니다. 자세한 사항은 문의하여 주시기 바랍니다.



세계의 인간 인슐린 시장 : 적응증별, 브랜드별, 투여 경로별, 종류별, 작용 발현 시간별, 제품별, 지역별 예측과 기회(2025년) Global Human Insulin Market By Indication, By Brand, By Route of Administration, By Type, By Onset Time, By Products, By Region, Forecast & Opportunities, 2025
발행일 : 2020년 05월 페이지 정보 : 영문 121 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 인간 인슐린(Human Insulin) 시장을 조사했으며, 각 지역 시장 전망, 시장 역학, 주요 동향, 경쟁 상황 등의 정보를 제공하고, 전략적 제안을 제시하고 있습니다.

목차

제1장 제품 개요

제2장 조사 방법

제3장 세계의 인간 인슐린 시장에 대한 COVID-19의 영향

제4장 주요 요약

제5장 고객의 소리

제6장 인간 인슐린 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 적응증별(I형 당뇨병, II형 당뇨병)
    • 브랜드별(Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N)
    • 투여 경로별(피하, 경비, 정맥내, 경피, 경구, 기타)
    • 종류별(기초, Bolus, 프리믹스, 바이오시밀러, 전통적)
    • 작용 발현 시간별(급속 작용, 단시간 작용, 중간 작용, 장시간 작용, 초장시간 작용, 혼합전, 흡입)
    • 제품별(인슐린 펜, 인슐린 펌프, 주입 시스템, 주사)
    • 기업별(2019년)
    • 지역별
  • 시장 매력 지수

제7장 아시아태평양의 인간 인슐린 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 적응증별
    • 브랜드별
    • 투여 경로별
    • 종류별
    • 작용 발현 시간별
    • 제품별
    • 국가별
  • 시장 매력 지수
  • 아시아태평양 : 국가 분석
    • 중국의 인간 인슐린 시장 전망
    • 인도의 인간 인슐린 시장 전망
    • 일본의 인간 인슐린 시장 전망
    • 한국의 인간 인슐린 시장 전망
    • 싱가포르의 인간 인슐린 시장 전망
    • 호주의 인간 인슐린 시장 전망

제8장 유럽의 인간 인슐린 시장 전망

  • 시장 규모와 예측
    • 금액·수량별
  • 시장 점유율과 예측
    • 적응증별
    • 브랜드별
    • 투여 경로별
    • 종류별
    • 작용 발현 시간별
    • 제품별
    • 국가별
  • 시장 매력 지수
  • 유럽 : 국가 분석
    • 프랑스의 인간 인슐린 시장 전망
    • 독일의 인간 인슐린 시장 전망
    • 영국의 인간 인슐린 시장 전망
    • 이탈리아의 인간 인슐린 시장 전망
    • 러시아의 인간 인슐린 시장 전망
    • 스페인의 인간 인슐린 시장 전망

제9장 북미의 인간 인슐린 시장 전망

  • 시장 규모와 예측
    • 금액·수량별
  • 시장 점유율과 예측
    • 적응증별
    • 브랜드별
    • 투여 경로별
    • 종류별
    • 작용 발현 시간별
    • 제품별
    • 국가별
  • 시장 매력 지수
  • 북미 : 국가 분석
    • 미국의 인간 인슐린 시장 전망
    • 멕시코의 인간 인슐린 시장 전망
    • 캐나다의 인간 인슐린 시장 전망

제10장 남미의 인간 인슐린 시장 전망

  • 시장 규모와 예측
    • 금액·수량별
  • 시장 점유율과 예측
    • 적응증별
    • 브랜드별
    • 투여 경로별
    • 종류별
    • 작용 발현 시간별
    • 제품별
    • 국가별
  • 시장 매력 지수
  • 남미 : 국가 분석
    • 브라질의 인간 인슐린 시장 전망
    • 아르헨티나의 인간 인슐린 시장 전망
    • 콜롬비아의 인간 인슐린 시장 전망

제11장 중동 및 아프리카의 인간 인슐린 시장 전망

  • 시장 규모와 예측
    • 금액·수량별
  • 시장 점유율과 예측
    • 적응증별
    • 브랜드별
    • 투여 경로별
    • 종류별
    • 작용 발현 시간별
    • 제품별
    • 국가별
  • 시장 매력 지수
  • 중동 및 아프리카 : 국가 분석
    • 남아프리카공화국의 인간 인슐린 시장 전망
    • 사우디아라비아의 인간 인슐린 시장 전망
    • UAE의 인간 인슐린 시장 전망

제12장 시장 역학

  • 성장 촉진요인
  • 과제

제13장 시장 동향

제14장 경쟁 상황

  • 경쟁 전망
  • 주요 기업 개요
    • Nektar Therapeutics
    • MannKind Corporation
    • Novo Nordisk
    • Physicians Total Care, Inc.
    • Eli Lilly and Company
    • A-S Medication Solutions
    • REMEDYREPACK INC.
    • Sedico Co.
    • Sanofi Aventis
    • Pfizer Inc.
    • PerkinElmer
    • Merck
    • Biocon
    • Wockhardt
    • Julphal
    • Ypsomed AG
    • Becton Dickinson and Company
    • B. Braun Melsungen AG
    • Baxter
    • Tandem Diabetes Care, Inc.

제15장 전략적 추천사항

제16장 면책사항

KSM 20.06.02

Global human insulin market is expected to grow at a steady CAGR during forecast period. Growing geriatric population and increasing incidents of diabetic cases around globe are contributing to the growing demand for human insulin market, globally. Now a days, diabetes is not only restricted to geriatric population, but it is also common among youth. Also, the technological advancements have eradicated human physical activities leading to obesity and diabetes disorders which is directly influencing the growth of the market. Cost effectiveness can be considered as a major restraining factor for the market as everyone suffering from diabetes might not be able to afford insulin.

The global human insulin market is segmented on the basis of indication, brand, route of administration, type, onset type, products and region. Based on indication, market can be bifurcated into type I diabetes and type II diabetes. Type II diabetes is likely to hold the largest market share until 2025 as around 90% of the overall population has type II diabetes.

Based on regional analysis, North America dominated the human insulin market in 2019 due to large population base suffering from diabetes and presence of leading companies in countries like US and Canada.

Leading players in the global human insulin market include Nektar Therapeutics, MannKind Corporation, Novo Nordisk, Physicians Total Care, Inc., Eli Lilly and Company, A-S Medication Solutions, REMEDYREPACK INC., Sedico Co., Sanofi Aventis, Pfizer Inc., PerkinElmer, Merck, Biocon, Wockhardt, Julphal, Ypsomed AG, Becton Dickinson and Company, B. Braun Melsungen AG, Baxter and Tandem Diabetes Care, Inc., among others.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study

  • To analyze and forecast the market size of global human insulin market.
  • To classify and forecast global human insulin market based on indication, brand, route of administration, type, onset type, products and region.
  • To identify drivers and challenges for global human insulin market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global human insulin market.
  • To conduct pricing analysis for global human insulin market.
  • To identify and analyze the profile of leading players operating in global human insulin market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of hospitals/clinics across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the hospitals/clinics which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals/clinics and presence of all major players across the globe.

TechSci Research calculated the market size of global human insulin market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience

  • Hospitals/clinics, research institutes and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to human insulin
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as hospitals/clinics, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global human insulin market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Indication:

Type I Diabetes

Type II Diabetes

  • Market, By Brand:

Humulin R

Novolin R

Humulin N

Exubera

Afrezza

Novolin N

  • Market, By Route of Administration:

Subcutaneous

Nasal

Intravenous

Transdermal

Oral

Others

  • Market, By Type:

Basal

Bolus

Pre-mixed

Biosimilar

Traditional

  • Market, By Onset Time:

Rapid acting

Short-acting,

Intermediate acting

Long acting

Ultra-long acting

Pre-mixed

Inhaled

  • Market, By Products:

Insulin Pens

Insulin Pumps

Infusion System

Injection

  • Market, By Region:

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Singapore
  • Australia

Europe

  • France
  • Germany
  • United Kingdom
  • Italy
  • Russia
  • Spain

North America

  • United States
  • Mexico
  • Canada

South America

  • Brazil
  • Argentina
  • Colombia

Middle east & Africa

  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global human insulin market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Human Insulin Market

4. Executive Summary

5. Voice of Customer

6. Global Human Insulin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication (Type I Diabetes, Type II Diabetes)
    • 6.2.2. By Brand (Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N)
    • 6.2.3. By Route of administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others)
    • 6.2.4. By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional)
    • 6.2.5. By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled)
    • 6.2.6. By Products (Insulin Pens, Insulin Pumps, Infusion System, Injection)
    • 6.2.7. By Company (2019)
    • 6.2.8. By Region
  • 6.3. Market Attractiveness Index

7. Asia-Pacific Human Insulin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Brand
    • 7.2.3. By Route of Administration
    • 7.2.4. By Type
    • 7.2.5. By Onset Time
    • 7.2.6. By Products
    • 7.2.7. By Country
  • 7.3. Market Attractiveness Index
  • 7.4. Asia-Pacific: Country Analysis
    • 7.4.1. China Human Insulin Market Outlook
      • 7.4.1.1. Market Size & Forecast
        • 7.4.1.1.1. By Value
      • 7.4.1.2. Market Share & Forecast
        • 7.4.1.2.1. By Indication
        • 7.4.1.2.2. By Brand
        • 7.4.1.2.3. By Route of Administration
        • 7.4.1.2.4. By Type
        • 7.4.1.2.5. By Onset Time
        • 7.4.1.2.6. By Products
    • 7.4.2. India Human Insulin Market Outlook
      • 7.4.2.1. Market Size & Forecast
        • 7.4.2.1.1. By Value
      • 7.4.2.2. Market Share & Forecast
        • 7.4.2.2.1. By Indication
        • 7.4.2.2.2. By Brand
        • 7.4.2.2.3. By Route of Administration
        • 7.4.2.2.4. By Type
        • 7.4.2.2.5. By Onset Time
        • 7.4.2.2.6. By Products
    • 7.4.3. Japan Human Insulin Market Outlook
      • 7.4.3.1. Market Size & Forecast
        • 7.4.3.1.1. By Value
      • 7.4.3.2. Market Share & Forecast
        • 7.4.3.2.1. By Indication
        • 7.4.3.2.2. By Brand
        • 7.4.3.2.3. By Route of Administration
        • 7.4.3.2.4. By Type
        • 7.4.3.2.5. By Onset Time
        • 7.4.3.2.6. By Products
    • 7.4.4. South Korea Human Insulin Market Outlook
      • 7.4.4.1. Market Size & Forecast
        • 7.4.4.1.1. By Value
      • 7.4.4.2. Market Share & Forecast
        • 7.4.4.2.1. By Indication
        • 7.4.4.2.2. By Brand
        • 7.4.4.2.3. By Route of Administration
        • 7.4.4.2.4. By Type
        • 7.4.4.2.5. By Onset Time
        • 7.4.4.2.6. By Products
    • 7.4.5. Singapore Human Insulin Market Outlook
      • 7.4.5.1. Market Size & Forecast
        • 7.4.5.1.1. By Value
      • 7.4.5.2. Market Share & Forecast
        • 7.4.5.2.1. By Indication
        • 7.4.5.2.2. By Brand
        • 7.4.5.2.3. By Route of Administration
        • 7.4.5.2.4. By Type
        • 7.4.5.2.5. By Onset Time
        • 7.4.5.2.6. By Products
    • 7.4.6. Australia Human Insulin Market Outlook
      • 7.4.6.1. Market Size & Forecast
        • 7.4.6.1.1. By Value
      • 7.4.6.2. Market Share & Forecast
        • 7.4.6.2.1. By Indication
        • 7.4.6.2.2. By Brand
        • 7.4.6.2.3. By Route of Administration
        • 7.4.6.2.4. By Type
        • 7.4.6.2.5. By Onset Time
        • 7.4.6.2.6. By Products

8. Europe Human Insulin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Brand
    • 8.2.3. By Route of Administration
    • 8.2.4. By Type
    • 8.2.5. By Onset Time
    • 8.2.6. By Products
    • 8.2.7. By Country
  • 8.3. Market Attractiveness Index
  • 8.4. Europe: Country Analysis
    • 8.4.1. France Human Insulin Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Indication
        • 8.4.1.2.2. By Brand
        • 8.4.1.2.3. By Route of Administration
        • 8.4.1.2.4. By Type
        • 8.4.1.2.5. By Onset Time
        • 8.4.1.2.6. By Products
    • 8.4.2. Germany Human Insulin Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Indication
        • 8.4.2.2.2. By Brand
        • 8.4.2.2.3. By Route of Administration
        • 8.4.2.2.4. By Type
        • 8.4.2.2.5. By Onset Time
        • 8.4.2.2.6. By Products
    • 8.4.3. United Kingdom Human Insulin Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Indication
        • 8.4.3.2.2. By Brand
        • 8.4.3.2.3. By Route of Administration
        • 8.4.3.2.4. By Type
        • 8.4.3.2.5. By Onset Time
        • 8.4.3.2.6. By Products
    • 8.4.4. Italy Human Insulin Market Outlook
      • 8.4.4.1. Market Size & Forecast
        • 8.4.4.1.1. By Value
      • 8.4.4.2. Market Share & Forecast
        • 8.4.4.2.1. By Indication
        • 8.4.4.2.2. By Brand
        • 8.4.4.2.3. By Route of Administration
        • 8.4.4.2.4. By Type
        • 8.4.4.2.5. By Onset Time
        • 8.4.4.2.6. By Products
    • 8.4.5. Russia Human Insulin Market Outlook
      • 8.4.5.1. Market Size & Forecast
        • 8.4.5.1.1. By Value
      • 8.4.5.2. Market Share & Forecast
        • 8.4.5.2.1. By Indication
        • 8.4.5.2.2. By Brand
        • 8.4.5.2.3. By Route of Administration
        • 8.4.5.2.4. By Type
        • 8.4.5.2.5. By Onset Time
        • 8.4.5.2.6. By Products
    • 8.4.6. Spain Human Insulin Market Outlook
      • 8.4.6.1. Market Size & Forecast
        • 8.4.6.1.1. By Value
      • 8.4.6.2. Market Share & Forecast
        • 8.4.6.2.1. By Indication
        • 8.4.6.2.2. By Brand
        • 8.4.6.2.3. By Route of Administration
        • 8.4.6.2.4. By Type
        • 8.4.6.2.5. By Onset Time
        • 8.4.6.2.6. By Products

9. North America Human Insulin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Brand
    • 9.2.3. By Route of Administration
    • 9.2.4. By Type
    • 9.2.5. By Onset Time
    • 9.2.6. By Products
    • 9.2.7. By Country
  • 9.3. Market Attractiveness Index
  • 9.4. North America: Country Analysis
    • 9.4.1. United States Human Insulin Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Indication
        • 9.4.1.2.2. By Brand
        • 9.4.1.2.3. By Route of Administration
        • 9.4.1.2.4. By Type
        • 9.4.1.2.5. By Onset Time
        • 9.4.1.2.6. By Products
    • 9.4.2. Mexico Human Insulin Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Indication
        • 9.4.2.2.2. By Brand
        • 9.4.2.2.3. By Route of Administration
        • 9.4.2.2.4. By Type
        • 9.4.2.2.5. By Onset Time
        • 9.4.2.2.6. By Products
    • 9.4.3. Canada Human Insulin Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Indication
        • 9.4.3.2.2. By Brand
        • 9.4.3.2.3. By Route of Administration
        • 9.4.3.2.4. By Type
        • 9.4.3.2.5. By Onset Time
        • 9.4.3.2.6. By Products

10. South America Human Insulin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Brand
    • 10.2.3. By Route of Administration
    • 10.2.4. By Type
    • 10.2.5. By Onset Time
    • 10.2.6. By Products
    • 10.2.7. By Country
  • 10.3. Market Attractiveness Index
  • 10.4. South America: Country Analysis
    • 10.4.1. Brazil Human Insulin Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Indication
        • 10.4.1.2.2. By Brand
        • 10.4.1.2.3. By Route of Administration
        • 10.4.1.2.4. By Type
        • 10.4.1.2.5. By Onset Time
        • 10.4.1.2.6. By Products
    • 10.4.2. Argentina Human Insulin Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Indication
        • 10.4.2.2.2. By Brand
        • 10.4.2.2.3. By Route of Administration
        • 10.4.2.2.4. By Type
        • 10.4.2.2.5. By Onset Time
        • 10.4.2.2.6. By Products
    • 10.4.3. Colombia Human Insulin Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Indication
        • 10.4.3.2.2. By Brand
        • 10.4.3.2.3. By Route of Administration
        • 10.4.3.2.4. By Type
        • 10.4.3.2.5. By Onset Time
        • 10.4.3.2.6. By Products

11. Middle East and Africa Human Insulin Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Indication
    • 11.2.2. By Brand
    • 11.2.3. By Route of Administration
    • 11.2.4. By Type
    • 11.2.5. By Onset Time
    • 11.2.6. By Products
    • 11.2.7. By Country
  • 11.3. Market Attractiveness Index
  • 11.4. MEA: Country Analysis
    • 11.4.1. South Africa Human Insulin Market Outlook
      • 11.4.1.1. Market Size & Forecast
        • 11.4.1.1.1. By Value
      • 11.4.1.2. Market Share & Forecast
        • 11.4.1.2.1. By Indication
        • 11.4.1.2.2. By Brand
        • 11.4.1.2.3. By Route of Administration
        • 11.4.1.2.4. By Type
        • 11.4.1.2.5. By Onset Time
        • 11.4.1.2.6. By Products
    • 11.4.2. Saudi Arabia Human Insulin Market Outlook
      • 11.4.2.1. Market Size & Forecast
        • 11.4.2.1.1. By Value
      • 11.4.2.2. Market Share & Forecast
        • 11.4.2.2.1. By Indication
        • 11.4.2.2.2. By Brand
        • 11.4.2.2.3. By Route of Administration
        • 11.4.2.2.4. By Type
        • 11.4.2.2.5. By Onset Time
        • 11.4.2.2.6. By Products
    • 11.4.3. UAE Human Insulin Market Outlook
      • 11.4.3.1. Market Size & Forecast
        • 11.4.3.1.1. By Value
      • 11.4.3.2. Market Share & Forecast
        • 11.4.3.2.1. By Indication
        • 11.4.3.2.2. By Brand
        • 11.4.3.2.3. By Route of Administration
        • 11.4.3.2.4. By Type
        • 11.4.3.2.5. By Onset Time
        • 11.4.3.2.6. By Products

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Players Profiled (Leading Companies)
    • 14.2.1. Nektar Therapeutics
    • 14.2.2. MannKind Corporation
    • 14.2.3. Novo Nordisk
    • 14.2.4. Physicians Total Care, Inc.
    • 14.2.5. Eli Lilly and Company
    • 14.2.6. A-S Medication Solutions
    • 14.2.7. REMEDYREPACK INC.
    • 14.2.8. Sedico Co.
    • 14.2.9. Sanofi Aventis
    • 14.2.10. Pfizer Inc.
    • 14.2.11. PerkinElmer
    • 14.2.12. Merck
    • 14.2.13. Biocon
    • 14.2.14. Wockhardt
    • 14.2.15. Julphal
    • 14.2.16. Ypsomed AG
    • 14.2.17. Becton Dickinson and Company
    • 14.2.18. B. Braun Melsungen AG
    • 14.2.19. Baxter
    • 14.2.20. Tandem Diabetes Care, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

Back to Top
전화 문의
F A Q